Anastrozole – Forschung

Effectiveness of Hormonal Therapy for Post-Menopausal Women with Hormone Receptor-Positive Advanced Breast Cancer: A Systematic Review and Meta-Analysis of Clinical Trials

Einfach gesagt: Although newer combination therapies are being adopted, the agents explored in this review are still widely used in clinical practice for HR+ BC.

Okwor VC, Okwor JC, Ukwuoma MK, Mitha SB, Nweke MC. · Medical principles and practice : international journal of the Kuwait University, Health Science Centre (2025)

A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer.

Robertson JFR, Jiang Z, Di Leo A, Ohno S, Pritchard KI, Ellis M · Breast Cancer (2019)

Body mass index and clinical outcomes in breast cancer patients undergoing endocrine therapy: A meta-analysis and Mendelian randomization study

Einfach gesagt: However, BMI should be considered in anastrozole therapy due to differential effects on DFS and adverse events.

Lin X, Sun H, Wei X, Xie M, Chen L, Hu CT, Cai J. · Clinical nutrition ESPEN (2025)

Bioequivalence of Oral Formulations of Anastrozole in Healthy Chinese Male Volunteers: A Randomized, Single-Dose, Two-Period, Two-Sequence Crossover Study.

Chen J, Zhuang J, Wu J, Chen X, Wang X, Huang L · Clin Pharmacol Drug Dev (2019)

Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer.

Robertson JFR, Cheung KL, Noguchi S, Shao Z, Degboe A, Lichfield J · Eur J Cancer (2018)

Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.

Dowsett M, Sestak I, Regan MM, Dodson A, Viale G, Thürlimann B · J Clin Oncol (2018)

Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early-Stage Breast Cancer.

Cairns J, Kalari KR, Ingle JN, Shepherd LE, Ellis MJ, Goss PE · Clin Pharmacol Ther (2021)

Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609).

Liang X, Briaux A, Becette V, Benoist C, Boulai A, Chemlali W · J Hematol Oncol (2018)

Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia.

Sestak I, Blake GM, Patel R, Coleman RE, Cuzick J, Eastell R · Bone (2019)

Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure.

van Hellemond IEG, Vriens IJH, Peer PGM, Swinkels ACP, Smorenburg CH, Seynaeve CM · Int J Cancer (2019)

Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer.

Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR · N Engl J Med (2019)

Absence of Drug-Drug Interaction of Anastrozole on Levonorgestrel Delivered Simultaneously by an Intravaginal Ring: Results of a Phase 2 Trial.

Nave R, Mellinger U, Klein S, Höchel J, Schmitz H · J Clin Pharmacol (2019)

Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study).

Kim JY, Im SA, Jung KH, Ro J, Sohn J, Kim JH · Eur J Cancer (2018)

Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action.

Cairns J, Ingle JN, Dudenkov TM, Kalari KR, Carlson EE, Na J · JCI Insight (2020)

Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study.

van Hellemond IEG, Smorenburg CH, Peer PGM, Swinkels ACP, Seynaeve CM, van der Sangen MJC · Int J Cancer (2019)

Effect of Testosterone on Natriuretic Peptide Levels.

Bachmann KN, Huang S, Lee H, Dichtel LE, Gupta DK, Burnett JC · J Am Coll Cardiol (2019)

Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II.

Sestak I, Smith SG, Howell A, Forbes JF, Cuzick J · Ann Oncol (2018)

Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer.

Gnant M, Fitzal F, Rinnerthaler G, Steger GG, Greil-Ressler S, Balic M · N Engl J Med (2021)

Adjunctive Statistical Standardization of Adjuvant Estrogen Receptor and Progesterone Receptor in Canadian Cancer Trials Group MA.27 Postmenopausal Breast Cancer Trial of Exemestane Versus Anastrozole.

Chapman JW, Bayani J, SenGupta S, Bartlett JMS, Piper T, Quintayo MA · J Clin Oncol (2024)

Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial.

Cuzick J, Sestak I, Forbes JF, Dowsett M, Cawthorn S, Mansel RE · Lancet (2020)